Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Oncolytics Biotech Inc. (NASDAQ:ONCY) has been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $6.25.

A number of analysts recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. HC Wainwright boosted their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Finally, Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th.

Oncolytics Biotech Trading Up 27.0%

Shares of ONCY stock opened at $1.06 on Friday. The stock has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $1.07. The company has a market cap of $112.51 million, a price-to-earnings ratio of -3.79 and a beta of 0.99. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.51.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. On average, equities analysts forecast that Oncolytics Biotech will post -0.28 earnings per share for the current fiscal year.

Insider Transactions at Oncolytics Biotech

In other news, Director Bernd R. Seizinger purchased 40,000 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was acquired at an average price of $0.85 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the director directly owned 566,991 shares in the company, valued at $481,942.35. This represents a 7.59% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Wayne Pisano purchased 30,000 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of $0.84 per share, with a total value of $25,200.00. Following the purchase, the director directly owned 492,414 shares in the company, valued at approximately $413,627.76. The trade was a 6.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 389,232 shares of company stock worth $348,084 over the last ninety days. 0.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONCY. Citadel Advisors LLC acquired a new position in shares of Oncolytics Biotech in the third quarter valued at approximately $535,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Oncolytics Biotech in the 4th quarter worth approximately $29,000. Tocqueville Asset Management L.P. acquired a new position in Oncolytics Biotech in the 4th quarter valued at $63,000. CIBC Private Wealth Group LLC purchased a new position in shares of Oncolytics Biotech during the 4th quarter worth $44,000. Finally, Scientech Research LLC purchased a new position in shares of Oncolytics Biotech during the 3rd quarter worth $25,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Oncolytics Biotech News Roundup

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.